NCT07121335 SMC Radiation Oncology SABR Cohort for Oligometastasis
| NCT ID | NCT07121335 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | Stereotactic Body Radiation Therapy (SBRT) |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-05-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer. The main questions it aims to answer are: 1. oncologic outcomes (progression-free survival, local failure rate), 2. patient-reported outcomes, 3. physician-assessed toxicity, and 4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.
Eligibility Criteria
Inclusion Criteria: * Performance status (ECOG PS) 0-2 * Diagnosed with metastatic disease * Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions) Exclusion Criteria: * Patient with a history of prior radiotherapy to the site planned for SABR * Patients with concomitant brain metastases
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07121335 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stereotactic Body Radiation Therapy (SBRT). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07121335 currently recruiting?
Yes, NCT07121335 is actively recruiting participants. Contact the research team at nalee.kim@samsung.com for enrollment information.
Where is the NCT07121335 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07121335 clinical trial?
NCT07121335 is sponsored by Samsung Medical Center. The trial plans to enroll 60 participants.